Group 1 - The company is enhancing its business capabilities in diabetes GLP-1, weight loss drug semaglutide, and rare cancer diseases, indicating potential competitiveness against global pharmaceutical giants for overseas market expansion [1] - The company is actively pursuing international registration and certification for its proprietary products, aiming to address unmet clinical needs with innovative offerings, thereby improving the accessibility and affordability of vaccines and therapeutic products [1] - The company encourages stakeholders to monitor its regular reports for updates on overseas sales revenue [1]